Skip to main content
Skip to content

Duplicate Document

This document appears to be a copy. The original version is:

EFTA Document EFTA01394011
Case File
efta-efta01394011DOJ Data Set 10Correspondence

EFTA Document EFTA01394011

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01394011
Pages
0
Persons
0
Integrity
Loading PDF viewer...

Summary

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
GLDUS137 Forrestal Capital LLC SOF IV — Project Klein Exclusive deal Expected Closing Date: June 2018 Li Fund Secondary NeGP-led Secondary D Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at close E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of leverage No Average age at purchase 9 years Description - Motivated quality GP aiming to recapitalize and extend their 2007 mid- market pan-European fund while providing liquidity to LPs - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital Investment rationale / Glendower Team angle Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capital to exploit market dislocations For dear:akin pcaposec rjy. Tha pr reed above I .W s. flOt cliose-d. and these is no guarantee that st., 1 intestine'? wit c:amok:4e or !cart o' Ivbire invested portfc4io or that it Al bei avaliab4e or. aftei fultrRi due diligence. prove suitable for :30F Di This slide should be reed end reviewed in conjunction with the 'Important Infomiation and "Important Perfra mane Information and Notes to Investment Pedormance sections Glendower Capital STRICTLY CONFIDENTIAL CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0099940 CONFIDENTIAL SDNY_GM_00246124 EFTA01394011

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.